PDS Biotechnology Corporation — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report; quarterly financial results are not clearly provided in the supplied filing text.
Business context
PDS Biotechnology is a clinical-stage immunotherapy company developing cancer treatments and infectious-disease vaccines using its Versamune platform. Its lead candidate, PDS0101, is being evaluated in Phase 2 studies; other programs are earlier stage. The company has no approved products and has not generated commercial product revenue.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $7.9 million | $6.1 million |
| General and administrative expense | $7.0 million | $11.0 million |
| Operating loss | $14.9 million | $21.0 million |
| Net loss | $14.8 million | $7.0 million |
| Net loss per share, basic and diluted | $0.89 | $1.44 |
| Cash used in operating activities | $13.1 million | $18.1 million |
| Cash and cash equivalents at year-end | $28.8 million | $12.2 million |
Gross and operating margins are not meaningful because the company reported no product revenue. At December 31, 2020, total assets were $30.9 million, total liabilities $3.8 million, and stockholders’ equity $27.1 million. No financial borrowings are reported; liabilities included $0.6 million of operating lease obligations. Operating cash outflow was funded principally by equity offerings.
Changes versus FY2019
- Net loss increased by $7.8 million, while operating loss narrowed by $6.1 million. The comparison is affected by FY2019’s $13.3 million merger-related bargain purchase gain, which reduced that year’s reported net loss.
- R&D expense rose 30% to $7.9 million, primarily reflecting higher clinical manufacturing, clinical and preclinical study, and personnel costs. G&A fell 37%, including lower stock-based compensation and professional costs.
- Operating cash use declined by $4.9 million, principally because FY2019 included merger-related costs.
- Two 2020 public offerings generated approximately $29.0 million in net proceeds. Shares outstanding increased from 5.3 million at year-end 2019 to 22.3 million at year-end 2020, a substantial increase in the equity base.
Outlook, developments and risks
- Management estimated existing cash would fund operations and R&D for at least 12 months from the report date, while noting that funding needs depend on clinical progress and other uncertain factors. The company expects continued losses and anticipates needing additional capital; future equity financing may dilute shareholders.
- In March 2021, Brazil’s Ministry of Science, Technology and Innovation committed to funding up to approximately $60 million for development and commercialization of a Versamune-based COVID-19 vaccine. Funding is contingent on availability of government resources and regulatory authorization; it is a subsequent event, not FY2020 revenue or cash on hand.
- COVID-19 delayed two of three PDS0101 Phase 2 trial starts and continued to threaten enrollment, site operations and development timelines. All three studies had subsequently been initiated.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, dependence on external manufacturers, CROs and collaborators, competition, patent protection, and the need for additional financing. PDS0101 remains early in development; preliminary or early-stage results may not predict later outcomes.
- The filing describes PDS0101’s safety and efficacy potential based on early clinical and preclinical observations; these are not evidence of regulatory approval or established commercial effectiveness.
- Management reported disclosure controls and internal control over financial reporting effective at year-end and said previously identified material weaknesses were remediated. The auditor did not provide an opinion on internal control effectiveness.
Important facts for investors to verify
- Current cash, operating cash burn, and management’s runway estimate against actual subsequent spending and financing.
- Enrollment, safety, and efficacy updates from the PDS0101 Phase 2 trials, including the VERSATILE-002 and NCI studies.
- Whether the announced Brazilian funding becomes available, its conditions, and the consortium’s respective rights and obligations.
- Potential dilution from future offerings and remaining shelf-registration capacity; the company reported approximately $81 million of securities available under its shelf at year-end disclosures.
- Manufacturing scale-up, clinical supply, and the status and scope of relevant patents and licenses.